No Data
No Data
Vigil Neuroscience Price Target Maintained With a $13.00/Share by Wedbush
William Blair Initiates Vigil Neuroscience(VIGL.US) With Buy Rating
William Blair Remains a Buy on Vigil Neuroscience Inc (VIGL)
Express News | Vigil Neuroscience Presented Data Highlighting Its Oral Small Molecule Program, Including Its Lead Clinical Candidate VG-3927, In Two Oral Presentations At The AD/PD 2025 International Conference On Alzheimer's And Parkinson's Diseases
Vigil Neuroscience Presents Data on Its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD 2025 International Conference
Vigil Neuroscience Reports 2024 Results and Clinical Progress